Royce & Associates LP increased its stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) by 15.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,887,743 shares of the company’s stock after acquiring an additional 506,007 shares during the period. Royce & Associates LP’s holdings in SOPHiA GENETICS were worth $32,579,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS during the second quarter valued at approximately $9,809,000. Principal Financial Group Inc. grew its stake in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Sei Investments Co. bought a new position in SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Sowell Financial Services LLC bought a new position in SOPHiA GENETICS in the third quarter valued at approximately $2,865,000. Finally, Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS during the 2nd quarter worth approximately $866,000. Institutional investors own 31.59% of the company’s stock.
SOPHiA GENETICS Stock Performance
Shares of SOPH traded up $0.35 during midday trading on Friday, reaching $8.21. The stock had a trading volume of 623,058 shares, compared to its average volume of 670,550. The firm has a market cap of $688.74 million, a PE ratio of -7.53 and a beta of 1.09. The firm has a 50 day simple moving average of $7.65 and a 200-day simple moving average of $6.05. SOPHiA GENETICS SA has a one year low of $3.83 and a one year high of $8.98. The company has a current ratio of 2.29, a quick ratio of 2.16 and a debt-to-equity ratio of 0.70.
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). SOPHiA GENETICS had a negative net margin of 89.18% and a negative return on equity of 128.69%. The firm had revenue of $24.27 million during the quarter, compared to the consensus estimate of $24.03 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.94 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have weighed in on SOPH. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of SOPHiA GENETICS in a research report on Monday, October 12th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $10.00.
Get Our Latest Research Report on SOPH
Insider Buying and Selling at SOPHiA GENETICS
In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 40,172 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $326,598.36. Following the transaction, the chairman owned 3,395,650 shares of the company’s stock, valued at $27,606,634.50. The trade was a 1.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $8.91, for a total value of $89,100.00. Following the completion of the sale, the insider owned 556,887 shares in the company, valued at $4,961,863.17. This represents a 1.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 153,162 shares of company stock valued at $1,240,254 in the last three months. Corporate insiders own 4.88% of the company’s stock.
SOPHiA GENETICS Company Profile
SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.
Further Reading
- Five stocks we like better than SOPHiA GENETICS
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding SOPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report).
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
